In summary, during the last decade by far the most outstanding advantage has been achieved in HER2/neu-overexpressing MBC. Introduction of bevacizumab as being a VEGF-directed qualified treatment method remains a concern on discussion. A lot of the novel therapeutics to the breast cancer armamentarium resulted in prolongation of survival https://judyv742luf0.blogaritma.com/profile